{"url_path":"/sec/maia/8-k/2026-05-14/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 ****Termination","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1878313/0001493152-26-023168-index.html","accession_number":"0001493152-26-023168","cik":"0001878313","ticker":"MAIA","issuer_name":"MAIA Biotechnology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1878313/0001493152-26-023168-index.html","primary_entity_key":"0001878313","primary_entity_name":"MAIA Biotechnology, Inc."},"word_count":184,"has_tables":true,"body_markdown":"**Item\n1.02****Termination\nof a Material Definitive Agreement.**\n\n \n\nOn\nMay 14, 2026, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common\nStock”), pursuant to that certain At The Market Offering Agreement dated February 14, 2024, or the sales agreement, between the\nCompany and H.C. Wainwright & Co., LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice\nto the Agent that it is terminating the sales agreement, which termination will be effective 7-business days after May 14, 2026, in accordance\nwith the terms of the sales agreement. Since filing of the March 28, 2025 prospectus supplement for up to $11,200,000 under the sales\nagreement, we have offered and sold 3,116,012 shares of common stock for gross proceeds of approximately $5,680,924 pursuant to the sales\nagreement.\n\n \n\n2\n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDated:\nMay 14, 2026\n\n \n\n \nMAIA\nBIOTECHNOLOGY, INC.\n\n \n \n \n\n \nBy:\n\n*/s/\nVlad Vitoc*\n\n \nName:\nVlad\nVitoc\n\n \nTitle:\nChief\nExecutive Officer\n\n \n\n3"}